Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. (Q48136699)

9 February 2018

title

Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. (English)

1 reference

9 February 2018

0 references

0 references

Alexandros Makriyannis

6

object named as

A Makriyannis

1 reference

9 February 2018

S González

1

1 reference

9 February 2018

J Romero

2

1 reference

9 February 2018

R de Miguel

3

1 reference

9 February 2018

I Lastres-Becker

4

1 reference

9 February 2018

M A Villanua

5

1 reference

9 February 2018

J A Ramos

7

1 reference

9 February 2018

J J Fernández-Ruiz

8

1 reference

9 February 2018

language of work or name

English

0 references

publication date

1 January 1999

1 reference

9 February 2018

published in

Life Sciences

1 reference

9 February 2018

volume

65

1 reference

9 February 2018

issue

3

1 reference

9 February 2018

page(s)

327-336

1 reference

9 February 2018

Search for endogenous ligands of the cannabinoid receptor

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Pharmacology of cannabinoid CB1 and CB2 receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

The cannabinoid receptor: biochemical, anatomical and behavioral characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Molecular characterization of a peripheral receptor for cannabinoids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Medicinal applications of delta-9-tetrahydrocannabinol and marijuana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Functional role of high-affinity anandamide transport, as revealed by selective inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Interactions between synthetic vanilloids and the endogenous cannabinoid system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Formation and inactivation of endogenous cannabinoid anandamide in central neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Potentiation of anandamide hypotension by the transport inhibitor, AM404

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs).

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Cannabinoid receptor binding did not vary in several hypothalamic nuclei after hypothalamic deafferentation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Effects of delta-9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Acute effects of delta 9-tetrahydrocannabinol on tuberoinfundibular dopamine activity, anterior pituitary sensitivity to dopamine and prolactin release vary as a function of estrous cycle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Neuronal localization of cannabinoid receptors in the basal ganglia of the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

delta 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Measurement of GABA in rat brain microdialysates using o-phthaldialdehyde-sulphite derivatization and high-performance liquid chromatography with electrochemical detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Effects of repeated administration of estradiol benzoate on tubero-infundibular GABAergic activity in male rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Highly sensitive assay for tyrosine hydroxylase activity by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

Cyclosporine modifies the pulsatile secretory patterns of prolactin and luteinizing hormone in normal and pituitary-grafted female rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

γ-Aminobutyric acid (GABAB) receptor-mediated inhibition of tyrosine hydroxylase activity in the striatum of rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

GABAB receptor activation partially inhibits N-methyl-D-aspartate-mediated tyrosine hydroxylase stimulation in rat striatal slices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900251-9

10.1016/S0024-3205(99)00251-9

7 January 2021

Identifiers

DOI

1 reference

9 February 2018

PubMed ID

10447218

1 reference

9 February 2018